

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of)	Attorney Docket No.: STURK0003
RESKI, Ralf, et al.)	Confirmation No. 9421
Serial No.: 10/089,450)	Group Art Unit: 1638
Filed: March 29, 2002)	Examiner: Anne R. KUBELIK
For: METHOD FOR THE PRODUCTION OF)	Date: May 16, 2008
PROTEINACEOUS SUBSTANCES)	

INFORMATION DISCLOSURE STATEMENT

MAIL STOP: AMENDMENT

United States Patent and Trademark Office
Customer Service Window
Randolph Building
401 Dulany Street
Alexandria, VA 22314

Sir:

In accordance with the duty of disclosure as set forth in 37 C.F.R. §1.56, this Information Disclosure Statement in connection with the above-identified application is being filed in accordance with 37 C.F.R. §1.97(b):

- ☐ within three months of the filing date of this application (not a C.P.A.);
- ☐ within three months of the date of entry of the National Stage;
before the mailing date of a first Office Action on the merits; or
- ☒ before the mailing of a first Office Action on the merits of, after the filing of a Request for Continued Examination (RCE) under §1.114.

A copy of each non-U.S. document identified on the attached Forms PTO/SB/08A and PTO/SB/08B is attached, however, in accordance with Official Gazette Notice dated August 5, 2003, copies of the U.S. patents and patent application publications are not attached.


Listed under Foreign Patent Documents Cite No. 1 relates to a Production of Secreted Foreign Polypeptides in Plant Cell Culture. Listed under Non Patent Literature Cite No.01 relates to High-Level Expression of Secreted Complex Glycosylated Recombinant Human Erythropoietin in the Physcomitrella. Cite No. 2 relates to Characterization of a Human Glycoprotein (erythropoietin) Produced in Cultured Tobacco Cells. Cite No. 3 relates to Ion Relations of Symplastic and Apoplastic Space in Leaves from Spinacia Oleracea L. and Pisum Sativum L. Under Salinity Document Cite No. 4 relates to a Cell Structure and Function. Cite No. 5 relates to a Fate of a Mutant Macrochloroplast in Somatic Hybrids. Their relevance is believed to be clear from their abstracts, when present, and or from the contents of the documents themselves. Accordingly, no further comment with regard to the disclosures of these documents is believed to be required.

It is respectfully requested that the attached documents be considered and officially cited, and that the Examiner initial a copy of Forms PTO/SB/08A and PTO/SB/08B, and return them to the undersigned to indicate that the documents have been considered.

It is believed that the present Information Disclosure Statement complies with the requirements of 37 C.F.R. §§ 1.97-8, but should the filing of this paper necessitate a fee, the Director is hereby authorized to charge the necessary fee to Deposit Account No. 50-1281.

Respectfully submitted,

GRIFFIN & SZIPL, PC


Joerg-Uwe Szipl
Registration No. 31,799

GRIFFIN & SZIPL, PC
Suite PH-1
2300 Ninth Street, South
Arlington, VA 22204
Telephone: (703) 979-5700
Facsimile: (703) 979-7429
E-mail: GandS@szipl.com
Customer No.: 24203